Biodesix hires co-CMO from acquired company

BOULDER  — Lung-cancer testing company Biodesix Inc. has hired a second chief medical officer away from a company it had purchased assets from earlier this year.

In a press release, the Boulder company said it had hired Dr. James Jett, a Denver lung doctor and former chief medical officer at U.K.-based Oncimmune Ltd. to serve alongside Dr. Steven Springmeyer, the company’s top doctor since last year.

“Biodesix is a natural continuation of my gratifying career as a physician. I believe that the future of patient care in oncology and pulmonology should be designed and innovated with the patient experience as the highest priority,” Jett said in a prepared statement.

SPONSORED CONTENT

How dispatchable resources enable the clean energy transition

Platte River must prepare for the retirement of 431 megawatts (MW) of dispatchable, coal-fired generation by the end of the decade and address more frequent extreme weather events that can bring dark calms (periods when there is no sun or wind).

Jett’s hire comes months after Biodesix purchased all of Oncimmune’s American assets in June, including a different lung-cancer test to what the company produces and a laboratory in De Soto, Kansas.

The company also secured a patent for one of its blood-testing devices last week.